about
Etiology and Complications of Portal Vein ThrombosisSoluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertensionNovel role of nuclear receptor Rev-erbĪ± in hepatic stellate cell activation: potential therapeutic target for liver injuryVascular hyporesponsiveness to angiotensin II in rats with CCl(4)-induced liver cirrhosisAtorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthaseCirculating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection.The role of miRNA-34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS.Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 inductionPRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertensionObeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.Future therapy of portal hypertension in liver cirrhosis - a guess.Deficiency in four and one half LIM domain protein 2 (FHL2) aggravates liver fibrosis in miceHemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver CirrhosisCirculating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control StudyInterplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis.Mechanisms of extrahepatic vasodilation in portal hypertension.Liver Fibrosis in HIV Patients Receiving a Modern cART: Which Factors Play a Role?Experimental liver fibrosis research: update on animal models, legal issues and translational aspects.Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension.Mouse models of metabolic liver injury.Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis.Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals.Transient and 2-Dimensional Shear-Wave Elastography Provide Comparable Assessment of Alcoholic Liver Fibrosis and Cirrhosis.Agmatine (decarboxylated arginine), a modulator of liver cell homeostasis and proliferation.Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS.Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis.The carbon tetrachloride model in mice.Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis.Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy.The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure.Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosisCombined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers.Circulating microRNAs as a marker for liver injury in human immunodeficiency virus patients.Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosisAtorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells.
P50
Q26796515-A9513396-C886-4087-9F3D-C97AD4AD3163Q28537987-D276058A-DFD8-4B17-AE7D-BF796E4BD988Q28564897-C5761A55-33C7-42FF-9EC9-79AEC756B61BQ28574817-45AFC94A-624B-4E20-9B4C-681F38B32933Q28582593-992586F6-6EBA-4F7B-ABA2-4C41CFF84015Q30418874-8E8DD6C8-BD78-40D8-A20B-F2C9449187D0Q33961656-7B9361CE-D145-44AF-8EE0-631492C6AEBFQ34023700-97A1DE38-25A4-4502-AE51-25C208DD52F5Q34268818-5F74B2C5-985B-461A-8344-971AA4DE6521Q34386625-FBABF0CB-8BEE-495E-8727-007F6172D679Q34446521-A20E4663-817F-42E8-B13E-BBB72D8CCB86Q34545684-E3AB4729-1FBF-44D0-8610-F2A9022948C1Q35787734-BEAA0B85-7B1E-4B53-8456-DAD5A9713B1FQ35806035-17E582A7-361B-4C70-ADA5-3CC8B6A7CE71Q36339714-274AF4E2-62CB-40B4-8E3A-F833BDB63EE5Q37150625-048F9195-8628-4362-A132-964C10720D05Q37328254-48540DB7-8266-4613-815C-B9E29115F74DQ37363773-6DE6037E-6F09-4A0F-8CE1-E72B515658DEQ37604322-E302F047-798A-4139-8E40-DED49E923C8CQ38402052-9BB7335E-BFFC-4F34-9F17-324174AE9587Q38763423-317844B0-202E-4E3E-8CE8-3BD588E27DAFQ38831994-4273C254-E758-44B9-AF8D-576D8130F1FCQ40061540-4FB12077-330A-4121-A1FE-665AD2E57FFAQ40468793-956E673B-FAAD-4241-ADEC-3C8D8F9E9221Q40598780-87883699-6890-4041-808F-E94D8911021CQ40772599-A75D5CC5-7D94-44AB-BBE7-7D98CC1D34B6Q41029212-FFF4699D-2544-4C05-99BD-E2B81B601E3FQ41068027-51B97298-0B84-4A23-9882-6AD005F22D6FQ41121854-BA41FFCF-8CEA-4920-95F1-29659412269DQ41416491-53403DE5-98AC-4482-8E62-4348EF0B4D2BQ41499594-6546CC10-1152-4DEF-BB6F-A6EF3DE5FB80Q41546237-23868339-8F76-402E-943D-B942803D3866Q41728844-77AF73FA-CBE9-41D7-86F0-A48D811A2114Q41739030-A5981715-17E2-4AED-9F47-D16BE9BB86EAQ41870298-38DD401E-44DE-4BC0-928D-B2E9C045B65FQ42199114-46E72244-86E2-42FA-973C-2EBB10335DB2Q42199832-F4D9B686-FD7A-46B9-B2D4-CD5A7249558FQ42667685-B2C0290E-DFE9-431C-8C19-24083E197462Q42847799-653FFAC4-3CBC-466D-8BDE-D06FC12C0137Q42969190-42D15651-4ED7-4CED-97CE-4EFBA19033D1
P50
description
researcher
@en
wetenschapper
@nl
Õ°Õ„ÕæÕ”Õ¦ÕøÕæÕøÕ²
@hy
name
Jonel Trebicka
@ast
Jonel Trebicka
@en
Jonel Trebicka
@es
Jonel Trebicka
@nl
Jonel Trebicka
@sl
type
label
Jonel Trebicka
@ast
Jonel Trebicka
@en
Jonel Trebicka
@es
Jonel Trebicka
@nl
Jonel Trebicka
@sl
prefLabel
Jonel Trebicka
@ast
Jonel Trebicka
@en
Jonel Trebicka
@es
Jonel Trebicka
@nl
Jonel Trebicka
@sl
P106
P31
P496
0000-0002-7028-3881